

Dario Cattaneo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7905150/publications.pdf>

Version: 2024-02-01

158
papers

5,115
citations

126708

33
h-index

102304

66
g-index

159
all docs

159
docs citations

159
times ranked

6290
citing authors

#	ARTICLE	IF	CITATIONS
1	Delayed graft function in kidney transplantation. <i>Lancet, The</i> , 2004, 364, 1814-1827.	6.3	828
2	Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 341-358.	2.2	276
3	Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1007-1018.	3.0	224
4	Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. <i>Kidney International</i> , 2002, 62, 1060-1067.	2.6	214
5	Hepatitis C Infection and Chronic Renal Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 207-220.	2.2	184
6	Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. <i>Clinical Infectious Diseases</i> , 2020, 71, 2276-2278.	2.9	182
7	How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2898-2908.	3.0	156
8	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , 2011, 25, 47-57.	1.2	116
9	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. <i>Kidney International</i> , 2002, 61, 1635-1645.	2.6	103
10	Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 586-589.	1.1	99
11	Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. <i>Transplantation</i> , 2007, 84, 956-964.	0.5	94
12	C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. <i>Pharmacogenomics</i> , 2007, 8, 1127-1141.	0.6	86
13	Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. <i>Aids</i> , 2007, 21, 2409-2415.	1.0	86
14	Population Pharmacokinetics of Mycophenolic Acid. <i>Clinical Pharmacokinetics</i> , 2008, 47, 827-838.	1.6	79
15	Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. <i>Clinical Transplantation</i> , 2001, 15, 402-409.	0.8	75
16	Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies. <i>Circulation</i> , 2003, 107, 586-592.	1.6	65
17	ABCB1 Genotypes Predict Cyclosporine-Related Adverse Events and Kidney Allograft Outcome. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1404-1415.	3.0	60
18	Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 83-92.	1.0	59

#	ARTICLE	IF	CITATIONS
19	From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy. <i>American Journal of Transplantation</i> , 2004, 4, 299-310.	2.6	58
20	Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing. <i>American Journal of Transplantation</i> , 2004, 4, 1345-1351.	2.6	57
21	Whole-Blood Calcineurin Activity Is Not Predicted by Cyclosporine Blood Concentration in Renal Transplant Recipients. <i>Clinical Chemistry</i> , 2001, 47, 1679-1687.	1.5	56
22	Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 460-464.	1.3	55
23	Pharmacokinetics of Mycophenolate Sodium and Comparison with the Mofetil Formulation in Stable Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 1147-1155.	2.2	53
24	Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 533-544.	1.5	52
25	Darunavir does not prevent SARS-CoV-2 infection in HIV patients. <i>Pharmacological Research</i> , 2020, 157, 104826.	3.1	49
26	Therapeutic drug management of linezolid: a missed opportunity for clinicians?. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 728-731.	1.1	48
27	R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor- α in primary CNS lymphoma. <i>Blood</i> , 2019, 134, 252-262.	0.6	43
28	Perceptions and patterns of use of generic drugs among Italian Family Pediatricians: First round results of a web survey. <i>Health Policy</i> , 2012, 104, 247-252.	1.4	40
29	Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: Evidence from a safety study with pilot efficacy measures in adult dystrophic patients. <i>Pharmacological Research</i> , 2012, 65, 472-479.	3.1	40
30	Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 435-44.	1.4	40
31	A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. <i>Pharmacological Research</i> , 2011, 64, 210-217.	3.1	36
32	Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. <i>Bioanalysis</i> , 2016, 8, 275-283.	0.6	36
33	Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection. <i>Clinica Chimica Acta</i> , 2006, 364, 354-358.	0.5	35
34	Exposure-Related Effects of Atazanavir on the Pharmacokinetics of Raltegravir in HIV-1-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 782-786.	1.0	35
35	Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. <i>British Journal of Pharmacology</i> , 2010, 160, 1550-1560.	2.7	35
36	Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events. <i>PLoS ONE</i> , 2013, 8, e80242.	1.1	34

#	ARTICLE	IF	CITATIONS
37	Ibuprofenâ€™s arginine generates nitric oxide and has enhanced anti-inflammatory effects. <i>Pharmacological Research</i> , 2009, 60, 221-228.	3.1	31
38	High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 816, 99-105.	1.2	30
39	Comparison of the <i>In Vivo</i> Pharmacokinetics and <i>In Vitro</i> Dissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by Chewing. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6132-6136.	1.4	30
40	Development of an HPLCâ€™UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients. <i>Journal of Pharmaceutical Analysis</i> , 2016, 6, 396-403.	2.4	30
41	Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 319-327.	0.6	30
42	Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2704-2706.	1.3	30
43	Generic cyclosporine formulations: more open questions than answers. <i>Transplant International</i> , 2005, 18, 371-378.	0.8	29
44	Does lopinavir really inhibit SARS-CoV-2?. <i>Pharmacological Research</i> , 2020, 158, 104898.	3.1	29
45	Determination of Linezolid in Human Plasma by High-Performance Liquid Chromatography With Ultraviolet Detection. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 520-524.	1.0	27
46	Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?. <i>PLoS ONE</i> , 2015, 10, e0123670.	1.1	26
47	Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 774, 187-194.	1.2	25
48	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 86-92.	0.9	25
49	In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial. <i>Kidney International</i> , 2004, 65, 1084-1090.	2.6	24
50	Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 193-201.	0.9	24
51	Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. <i>Blood Advances</i> , 2020, 4, 3648-3658.	2.5	24
52	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARSâ€™CoVâ€™2 infection: A retrospective cohort study. <i>Journal of Medical Virology</i> , 2021, 93, 1421-1427.	2.5	24
53	Drugâ€™Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. <i>Drugs and Aging</i> , 2020, 37, 925-933.	1.3	23
54	Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 407-413.	1.0	22

#	ARTICLE	IF	CITATIONS
55	Pharmacovigilance knowledge in family paediatricians. A survey study in Italy. <i>Health Policy</i> , 2013, 113, 216-220.	1.4	21
56	Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 285-293.	0.8	21
57	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 64-68.	2.3	21
58	Second generation antipsychotics in "real-life" paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1-8.	1.0	20
59	Comparison of the Innofluor® certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. <i>Clinical Biochemistry</i> , 2006, 39, 1152-1159.	0.8	19
60	Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 927-935.	1.5	19
61	How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, e24-e26.	0.9	18
62	Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1842-1844.	1.3	18
63	Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational Study. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 197-201.	1.0	17
64	Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. , 2005, 15, 71-76.		16
65	Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure. <i>Frontiers in Pediatrics</i> , 2019, 7, 309.	0.9	16
66	Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: Not simply overestimation. <i>Clinica Chimica Acta</i> , 2005, 355, 153-164.	0.5	15
67	Determination of Atazanavir in Human Plasma by High-Performance Liquid Chromatography With UV Detection. <i>Journal of Chromatographic Science</i> , 2008, 46, 485-489.	0.7	15
68	Clinical Pharmacokinetics of Ibuprofen Arginine. <i>Current Clinical Pharmacology</i> , 2010, 5, 239-245.	0.2	15
69	Tenofovir-induced Renal Tubular Dysfunction in Vertically HIV-infected Patients Associated With Polymorphisms in ABCC2, ABCC4 and ABCC10 Genes. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e403-e405.	1.1	15
70	Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic. <i>AIDS Reviews</i> , 2019, 21, 40-49.	0.5	15
71	Cyclosporine Formulation and Kaposi's Sarcoma after Renal Transplantation. <i>Transplantation</i> , 2005, 80, 743-748.	0.5	14
72	Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-infected Patients. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 440-445.	1.0	14

#	ARTICLE	IF	CITATIONS
73	Dolutegravir Plasma Concentrations According to Companion Antiretroviral Drug: Unwanted Drug Interaction or Desirable Boosting Effect?. <i>Antiviral Therapy</i> , 2017, 22, 353-356.	0.6	14
74	The management of anti-infective agents in intensive care units: the potential role of a "fast" pharmacology. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 355-366.	1.3	14
75	Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2918-2920.	1.3	13
76	Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 245-252.	1.5	13
77	Effects of Rosuvastatin on Glomerular Capillary Size-Selectivity Function in Rats with Renal Mass Ablation. <i>American Journal of Nephrology</i> , 2007, 27, 630-638.	1.4	12
78	Long-term Renal Effects of Tenofovir-Disoproxil-Fumarate in Vertically HIV-Infected Children, Adolescents, and Young Adults: A 132-Month Follow-Up Study. <i>Clinical Drug Investigation</i> , 2015, 35, 419-426.	1.1	12
79	Is it time to revise linezolid dose in elderly patients?. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1335-1336.	0.8	12
80	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 103-109.	1.6	12
81	Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients: A Call for Action?. <i>Clinical Pharmacokinetics</i> , 2021, 60, 603-609.	1.6	12
82	Investigational drugs for diabetic nephropathy. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1487-1500.	1.9	11
83	Optimizing immunosuppressive drug dosing in pediatric renal transplantation. <i>Pharmacological Research</i> , 2012, 65, 163-167.	3.1	11
84	Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint. <i>Aids</i> , 2014, 28, 2477-2480.	1.0	11
85	Intolerance of dolutegravir-containing combination antiretroviral therapy. <i>Aids</i> , 2017, 31, 867-868.	1.0	11
86	Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1835-1844.	1.1	11
87	Are Non-Serious Adverse Reactions to Psychiatric Drugs Really Non-Serious?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 394-400.	0.7	10
88	Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 341.	0.7	10
89	Prolonged inductive effect of rifampicin on linezolid exposure. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 643-644.	0.8	10
90	Dosing Colistin Properly: Let's Save Our Last Resort Old Drug! <i>Clinical Infectious Diseases</i> , 2017, 65, 870-870.	2.9	10

#	ARTICLE	IF	CITATIONS
91	Dolutegravir and metformin. <i>Aids</i> , 2018, 32, 532-533.	1.0	10
92	Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?. <i>Pharmacopsychiatry</i> , 2018, 51, 270-271.	1.7	10
93	Emerging drugs for diabetic nephropathy. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 747-771.	1.0	9
94	Intraindividual and Interindividual Variability of Olanzapine Trough Concentrations in Patients Treated With the Long-Acting Injectable Formulation. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 365-369.	0.7	9
95	Selective serotonin reuptake inhibitorsâ€™ passage into human milk of lactating women. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019, 32, 3020-3025.	0.7	9
96	Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 64-74.	1.0	9
97	Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 34-45.	1.3	9
98	Comparison of the ARK Immunoassay With High-Performance Liquid Chromatography With Ultraviolet Detection for Therapeutic Drug Monitoring of Linezolid. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 140-143.	1.0	9
99	Development of a CE method for the determination of mycophenolic acid in human plasma: A comparison with HPLC. <i>Electrophoresis</i> , 2007, 28, 3908-3914.	1.3	8
100	Orlistat: weight lost at cost of HIV rebound. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1739-1741.	1.3	8
101	Loss of Control of HIV Viremia With OTC Weightâ€Loss Drugs: A Call for Caution?. <i>Obesity</i> , 2018, 26, 1251-1252.	1.5	8
102	Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 651-657.	1.3	8
103	Drugâ€Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. <i>Drugs and Aging</i> , 2021, 38, 341-346.	1.3	8
104	ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. <i>Pharmacogenomics Journal</i> , 2021, 21, 586-593.	0.9	8
105	In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111631.	2.5	8
106	Limited Sampling Strategies for the Estimation of Sirolimus Daily Exposure in Kidney Transplant Recipients on a Calcineurin Inhibitorâ€Free Regimen. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 773-781.	1.0	7
107	Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers. <i>Drug Design, Development and Therapy</i> , 2014, 8, 411.	2.0	7
108	When food can make the difference: The case of elvitegravir-based co-formulation. <i>International Journal of Pharmaceutics</i> , 2016, 512, 301-304.	2.6	7

#	ARTICLE	IF	CITATIONS
109	How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life?. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2271-2273.	1.3	7
110	Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 330-334.	1.0	7
111	Therapeutic Drug Monitoring of Antibiotics in the Elderly: A Narrative Review. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 75-85.	1.0	7
112	Serotonin Reuptake Inhibitors in Pregnancy: Can Genes Help Us in Predicting Neonatal Adverse Outcome?. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	6
113	Lights and Shadows of the Actual European Guidelines on Bioanalytical Method Validation. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 739-745.	1.0	6
114	Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disorder: A Prospective Observational Study. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 441-445.	1.0	6
115	Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1183-1192.	1.5	6
116	Use of Direct Oral Anticoagulants in People Living with HIV: A Single-Center Experience. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 999-1001.	1.5	6
117	Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. <i>Expert Opinion on Therapeutic Patents</i> , 2004, 14, 1553-1566.	2.4	5
118	Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?. <i>Journal of Hepatology</i> , 2006, 44, 837-838.	1.8	5
119	Acute kidney injury in a preterm infant homozygous for the C3435T polymorphism in the ABCB1 gene given oral morphine. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 431-433.	1.4	5
120	Is Chewed Raltegravir an Option to Care for HIV-Infected Patients With Active Tuberculosis?. <i>Clinical Infectious Diseases</i> , 2013, 57, 480-481.	2.9	5
121	Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 545-549.	1.1	5
122	Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 383-385.	0.8	5
123	Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1341-1345.	1.3	5
124	Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 559-572.	0.6	5
125	The Relevance of Drug-drug Interactions in Clinical Practice: The Case of Concomitant Boosted Protease Inhibitors plus Alpha-1 Blocker Administration. <i>Antiviral Therapy</i> , 2018, 23, 467-469.	0.6	5
126	Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, e17-e20.	0.9	5

#	ARTICLE	IF	CITATIONS
127	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 95-105.	0.2	4
128	Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 216-222.	1.0	4
129	Application of Quality by Design Approach to Bioanalysis: Development of a Method for Elvitegravir Quantification in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 531-542.	1.0	4
130	Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1177-1178.	0.8	4
131	Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 997-1004.	2.0	4
132	Mycophenolic Acid Formulation Affects Cyclosporine Pharmacokinetics in Stable Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 643-649.	1.0	3
133	Omega-3 Polyunsaturated Fatty Acids Affect Sirolimus Exposure in Kidney Transplant Recipients on Calcineurin Inhibitor-Free Regimen. <i>Transplantation</i> , 2010, 89, 126-127.	0.5	3
134	Severe Hyperbilirubinemia in an HIV-HCV Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 285-287.	1.0	3
135	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. <i>European Respiratory Journal</i> , 2016, 47, 1287-1288.	3.1	3
136	Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 365-367.	0.8	3
137	No effects of Hypericum-containing complex on dolutegravir plasma trough concentrations: a case report. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1467-1468.	0.8	3
138	Different effects of glucocorticoids on darunavir plasma concentrations. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 733-735.	0.8	3
139	Association of HIV Infection with Epilepsy and Other Comorbid Conditions. <i>AIDS and Behavior</i> , 2020, 24, 1051-1055.	1.4	3
140	Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report. <i>International Journal of STD and AIDS</i> , 2020, 31, 1008-1010.	0.5	3
141	Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. <i>Aids</i> , 2021, 35, 2551-2553.	1.0	3
142	Reply to "Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients". <i>Aids</i> , 2011, 25, 1012-1013.	1.0	2
143	Atypical pharmacokinetics of atazanavir in an HIV-infected patient. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 204-206.	1.0	2
144	Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 119-125.	1.0	2

#	ARTICLE	IF	CITATIONS
145	Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings. <i>Drugs in R and D</i> , 2020, 20, 155-160.	1.1	2
146	Case of Suboptimal Linezolid Exposure: Is There a Role for Pharmacogenetics?. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 347-348.	1.0	2
147	Doravirine/tenofovir disoproxil fumarate/lamivudine-induced alopecia: A case report. <i>International Journal of STD and AIDS</i> , 2022, , 095646242210962.	0.5	2
148	Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. <i>Personalized Medicine</i> , 2004, 1, 53-62.	0.8	1
149	Effect of hepatitis B and C clearance on atazanavir exposure. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1409-1411.	0.8	1
150	Determinants of bone diseases in tenofovir-treated HIV patients. <i>Aids</i> , 2016, 30, 1686-1687.	1.0	1
151	Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1345-1350.	1.6	1
152	Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1354-1356.	1.3	1
153	Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 791-792.	0.8	1
154	Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP. <i>Aids</i> , 2021, 35, 522-524.	1.0	1
155	Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". <i>Clinical Pharmacokinetics</i> , 2021, 60, 829-831.	1.6	1
156	Fosfomycin therapeutic drug monitoring in real-life: development and validation of a LC-MS/MS method on plasma samples. <i>Journal of Chemotherapy</i> , 2022, 34, 25-34.	0.7	1
157	Special Issue on the Therapeutic Drug Monitoring of Anti-infective Drugs: Editorial. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 1-2.	1.0	1
158	Identification of Different Patterns of Dabigatran In Vivo Bioactivation in Patients on Maintenance Anticoagulation Therapy. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 814-816.	1.0	0